FDA Puts Clozapine REMS Requirements on Temporary Hold

US regulators have put some of the new clozapine risk evaluation and mitigation strategy program on temporary hold because of start-up difficulties, including long telephone wait times.

Related Keywords

United States ,American , ,American Psychiatric Association ,Drug Administration ,Medscape Medical News ,Schizophrenia ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Schizoaffective Disorder ,Antipsychotics ,Neuroleptics ,Neuroleptic Drugs ,Patient Safety ,Practice Management ,Risk Evaluation And Mitigation Strategies Rems ,Neutropenia ,Pharmaceutical Services Insurance ,Prescription Drug Coverage ,Drug Coverage ,Drug Benefit ,Health Policy ,Health Care Quality Access Ev ,